Author: Kai Duan; Bende Liu; Cesheng Li; Huajun Zhang; Ting Yu; Jieming Qu; Min Zhou; Li Chen; Shengli Meng; Yong Hu; Cheng Peng; Mingchao Yuan; Jinyan Huang; Zejun Wang; Jianhong Yu; Xiaoxiao Gao; Dan Wang; Xiaoqi Yu; Li Li; Jiayou Zhang; Xiao Wu; Bei Li; Yanping Yu; Wei Chen; Yan Peng; Yeqin Hu; Lianzhen Lin; Xuefei Liu; Shihe Huang; Zhijun Zhou; Lianghao Zhang; Yue Wang; Zhi Zhang; Kun Deng; Zhiwu Xia; Qin Gong; Wei Zhang; Xiaobei Zheng; Ying Liu; Huichuan Yang; Dongbo Zhou; Ding Yu; Jifeng Hou; Zhengli Shi; Saijuan Chen; Zhu Chen; Xin-xin Zhang; Xiaoming Yang
Title: The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study Document date: 2020_3_23
ID: 8znnq0rh_32
Snippet: The results suggested that the inflammation and overreaction of the immune system were alleviated by antibodies contained in CP. The case-fatality rates (CFRs) in the present study were 0% (0/10), which was comparable to the CFRs in SARS which varied from 0% (0/10) to 12.5% (10/80) in four non-comparative studies using CP treatment (9, (20) (21) (22) . Based on our preliminary results, CP therapy can be an easy-accessible, promising and safe resc.....
Document: The results suggested that the inflammation and overreaction of the immune system were alleviated by antibodies contained in CP. The case-fatality rates (CFRs) in the present study were 0% (0/10), which was comparable to the CFRs in SARS which varied from 0% (0/10) to 12.5% (10/80) in four non-comparative studies using CP treatment (9, (20) (21) (22) . Based on our preliminary results, CP therapy can be an easy-accessible, promising and safe rescue option for severe COVID-19 patients. It is nevertheless worth mentioning that the absorption of pulmonary lesions was often behind the improvement of clinical symptoms, as shown in patients 9 and 10 in this trial.
Search related documents:
Co phrase search for related documents- case fatality and cp therapy: 1, 2
- case fatality and CP treatment: 1, 2, 3
- case fatality and immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- case fatality and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
- case fatality and SARS cfr: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- case fatality and severe patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- case fatality rate and clinical symptom: 1
- case fatality rate and cp therapy: 1, 2
- case fatality rate and CP treatment: 1, 2
- case fatality rate and immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9
- case fatality rate and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- case fatality rate and SARS cfr: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- case fatality rate and severe patient: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical symptom and CP treatment: 1
- clinical symptom and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- clinical symptom and severe patient: 1, 2, 3
- cp therapy and present study: 1, 2, 3, 4, 5, 6, 7, 8
- cp therapy and rescue option: 1
- cp therapy and severe patient: 1, 2
Co phrase search for related documents, hyperlinks ordered by date